Update on afatinib-based combination regimens for the treatment of EGFR mutation-positive non-small-cell lung cancer

EGFR TKI combination with immunotherapy in non-small cell lung cancer

(2017) Myung-Ju Ahn et al.   Expert Opinion On Drug Safety

Most T790M mutations are present on the same EGFR allele as activating mutations in patients with non–small cell lung cancer

(2017) Noriko Hidaka et al.   LUNG CANCER

Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer

(2017) Tony S. Mok et al.   NEW ENGLAND JOURNAL OF MEDICINE

Treatment Options for EGFR T790M-Negative EGFR Tyrosine Kinase Inhibitor-Resistant Non-Small Cell Lung Cancer

(2017) Salvatore Corallo et al.   Targeted Oncology

Phase Ib study of afatinib plus standard-dose cetuximab in patients with advanced solid tumours

(2016) A. Gazzah et al.   EUROPEAN JOURNAL OF CANCER

Afatinib-based combination regimens for the treatment of solid tumors: rationale, emerging strategies and recent progress

(2016) Jaafar Bennouna et al.   Future Oncology

Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial

(2016) Keunchil Park et al.   LANCET ONCOLOGY

Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trial

(2015) M. Schuler et al.   ANNALS OF ONCOLOGY

A Phase Ib/II Study of Afatinib in Combination with Nimotuzumab in Non-Small Cell Lung Cancer Patients with Acquired Resistance to Gefitinib or Erlotinib

(2015) J. Y. Lee et al.   CLINICAL CANCER RESEARCH

Upregulation of PD-L1 by EGFR Activation Mediates the Immune Escape in EGFR-Driven NSCLC: Implication for Optional Immune Targeted Therapy for NSCLC Patients with EGFR Mutation

(2015) Nan Chen et al.   Journal of Thoracic Oncology

Inhibition of IGF1R signaling abrogates resistance to afatinib (BIBW2992) in EGFR T790M mutant lung cancer cells

(2015) Yongik Lee et al.   MOLECULAR CARCINOGENESIS

AZD9291 in EGFR Inhibitor–Resistant Non–Small-Cell Lung Cancer

(2015) Pasi A. Jänne et al.   NEW ENGLAND JOURNAL OF MEDICINE

A decade of EGFR inhibition in EGFR-mutated non small cell lung cancer (NSCLC): Old successes and future perspectives

(2015) Alessandro Russo et al.   Oncotarget

Insulin-Like Growth Factor System in Cancer: Novel Targeted Therapies

(2015) Varsha P. Brahmkhatri et al.   Biomed Research International

Gefitinib-Integrated Regimen versus Chemotherapy Alone in Heavily Pretreated Patients with Epidermal Growth Factor Receptor–Mutated Lung Adenocarcinoma: A Case-Control Study

(2014) Nan-Jie Zhao et al.   Translational Oncology

Dual Inhibition of EGFR with Afatinib and Cetuximab in Kinase Inhibitor-Resistant EGFR-Mutant Lung Cancer with and without T790M Mutations

(2014) Y. Y. Janjigian et al.   Cancer Discovery

Chemotherapy With Erlotinib or Chemotherapy Alone in Advanced Non-Small Cell Lung Cancer With Acquired Resistance to EGFR Tyrosine Kinase Inhibitors

(2013) S. B. Goldberg et al.   ONCOLOGIST

Phase I/II Trial of Cetuximab and Erlotinib in Patients with Lung Adenocarcinoma and Acquired Resistance to Erlotinib

(2011) Y. Y. Janjigian et al.   CLINICAL CANCER RESEARCH

Dual Inhibition of the Epidermal Growth Factor Receptor with Cetuximab, an IgG1 Monoclonal Antibody, and Gefitinib, A Tyrosine Kinase Inhibitor, in Patients with Refractory Non-small Cell Lung Cancer (NSCLC): A Phase I Study

(2008) Suresh Ramalingam et al.   Journal of Thoracic Oncology

BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models

(2008) D Li et al.   ONCOGENE